AstraZeneca announced the availability of Bydureon (exenatide extended-release for injectable suspension) Pen in pharmacies across the country. Bydureon is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes.

Bydureon Pen is a prefilled, single-use injector that contains the same dose and formulation as the original Bydureon single-dose tray. The Pen formulation does not require the transfer of medication between a vial and syringe. The active ingredient, exenatide, is delivered via microsphere technology as a once-weekly dose.

RELATED: First Once-Weekly Diabetes Drug Approved

The Bydureon Pen is available as a 2mg strength pen in 4-count cartons. The Bydureon single-dose tray is still available for patients.

For more information call (877) 700-7365 or visit